advertisement
Abstract #126464 Published in IGR 25-2
Long-term Safety and Performance of a Suprachoroidal Pressure Sensor System: Results of the EYEMATE-SC Trial Follow-up Study
Micheletti E; Micheletti E; Mansouri K; Dick HB; Hoffmann EM; Mackert MJ; Weinreb RN; Szurman P;Ophthalmology 2025; 132: 775-784
See also comment(s) by Maria Chiara Rivolta & Alessandro Rabiolo •
PURPOSE: To evaluate the long-term safety and performance of the EYEMATE-SC sensor system, a suprachoroidal implantable diagnostic medical device designed for measuring intraocular pressure (IOP) in patients with glaucoma that offers direct digitized IOP readings in millimeters of mercury. DESIGN: This study is part of the prospective, open-label, multicenter interventional EYEMATE-SC trial. PARTICIPANTS: Twenty-two eyes of 22 patients with open-angle glaucoma who received the implant in conjunction with nonpenetrating glaucoma surgery (NPGS) were included in the study. METHODS: This 3-year follow-up study analyzed the long-term safety of the EYEMATE-SC suprachoroidal sensor system (Implandata). The telemetric sensor system includes an implantable IOP sensor and a handheld reading device. MAIN OUTCOME MEASURES: All patients underwent 5 follow-up visits over a 24-month follow-up period from month 12 to month 36 after implantation. Each visit consisted of a comprehensive examination including IOP measurement with the EYEMATE-SC system and Goldmann applanation tonometry (GAT). The agreement between GAT and the EYEMATE-SC was analyzed using Bland-Altman analysis. Adverse events (AEs) and device-related adverse events (ADEs) were recorded at all follow-up visits. RESULTS: Of 24 eligible patients of the EYEMATE-SC trial, 22 patients (mean age 65.0 ± 10.6 years, 54.5% female) were enrolled. The overall mean follow-up was 2.7 ± 0.6 years (range, 1.0-3.4 years). Limits of agreement between GAT and EYEMATE-SC IOP were -6.2 to 5.7 mmHg (mean absolute difference of 2.3 mmHg), with greatest concordance at 12 months (concordance correlation coefficient [rccc] = 0.802, N = 22) and 18 months (rccc = 0.854, N = 19). A difference of < 5 mmHg was recorded in > 85% of the 86 paired measurements. No serious AEs and ADEs were recorded. Most common AEs were raised IOP in 5 patients, reduced visual acuity in 3 patients, and cataract in 3 patients. CONCLUSIONS: This study demonstrates the long-term safety of the EYEMATE-SC system. No serious AEs related to the EYEMATE-SC were observed. The agreement between the EYEMATE-SC and GAT was within the standard range of IOP-measuring methods set by regulatory agencies. The EYEMATE-SC system is well tolerated and accurate for self- measurement of IOP throughout the day. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Moorfields Eye Hospital, London, United Kingdom.
Full article